N. Anthony Coles - 28 Dec 2022 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role: Director
Signature: By: Richard Gluckselig as attorney-in-fact For: N. Anthony Coles
Issuer symbol: REGN
Transactions as of: 28 Dec 2022
Net transactions value: -$1,565,412
Form type: 4
Filing time: 30 Dec 2022, 15:10:22 UTC
Previous filing: 13 Dec 2022
Next filing: 05 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	REGN	Common Stock	Options Exercise	$802,487	+2,145	+196%	$374.12	3,238	28 Dec 2022	Direct	F1
transaction	REGN	Common Stock	Options Exercise	$1,743,923	+3,613	+112%	$482.68	6,851	28 Dec 2022	Direct	F1
transaction	REGN	Common Stock	Sale	$128,124	-181	-2.6%	$707.87	6,670	28 Dec 2022	Direct	F1
transaction	REGN	Common Stock	Sale	$710	-1	-0.01%	$709.92	6,669	28 Dec 2022	Direct	F1
transaction	REGN	Common Stock	Sale	$482,518	-679	-10%	$710.63	5,990	28 Dec 2022	Direct	F1, F2
transaction	REGN	Common Stock	Sale	$71,195	-100	-1.7%	$711.95	5,890	28 Dec 2022	Direct	F1
transaction	REGN	Common Stock	Sale	$854,965	-1,198	-20%	$713.66	4,692	28 Dec 2022	Direct	F1, F3
transaction	REGN	Common Stock	Sale	$730,331	-1,022	-22%	$714.61	3,670	28 Dec 2022	Direct	F1, F4
transaction	REGN	Common Stock	Sale	$1,621,278	-2,266	-62%	$715.48	1,404	28 Dec 2022	Direct	F1, F5
transaction	REGN	Common Stock	Sale	$222,701	-311	-22%	$716.08	1,093	28 Dec 2022	Direct	F1, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	REGN	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-2,145	-100%	$0.000000^*	0	28 Dec 2022	Common Stock	2,145	$374.12	Direct	F1, F7
transaction	REGN	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-3,613	-100%	$0.000000^*	0	28 Dec 2022	Common Stock	3,613	$482.68	Direct	F1, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2	Represents volume-weighted average price of sales of 679 shares of Company stock on December 28, 2022 at prices ranging from $710.48 to $710.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price.
F3	Represents volume-weighted average price of sales of 1,198 shares of Company stock on December 28, 2022 at prices ranging from $713.17 to $713.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price.
F4	Represents volume-weighted average price of sales of 1,022 shares of Company stock on December 28, 2022 at prices ranging from $714.00 to $714.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price.
F5	Represents volume-weighted average price of sales of 2,266 shares of Company stock on December 28, 2022 at prices ranging from $715.04 to $715.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price.
F6	Represents volume-weighted average price of sales of 311 shares of Company stock on December 28, 2022 at prices ranging from $716.02 to $716.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price.
F7	On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.